The director of Centers for Neuropsychology and Neuroscience Research, and Traumatic Brain Injury Research at Kessler Foundation shared her perspective on the varying benefits different patient groups derive through strategy training for cognitive rehabilitation.
The study unearthed a 20% diagnostic error rate with non-sex-specific parameters—10% false negatives in women and 10% false positives in men—which the authors found may be eliminated with gender-specific norms and cut scores.
The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine discussed the importance of identifying and diagnosing obstructive sleep apnea as a prevention for a number of its consequential risk factors.
This is the first study to compare infection risk with rituximab alongside other highly effective disease-modifying therapies.
The latest generic entry comes on the heels of a new report from ICER, which published a list of prescription drugs that had substantial price increases in 2017 and 2018 without what they consider to be new supporting evidence.
The impact MT1621 had on survival probably for those treated in comparison to the natural history of the often-fatal disorder was highly significant, with all patients remaining alive as of October.
The senior director of Global Clinical Science at Takeda Pharmaceutical offered perspective on the development of TAK-925, an investigational selective orexin type-2 receptor agonist for the treatment of narcolepsy.
The centers will make all data freely available to the greater research community, including those in academia and industry.
The director of Centers for Neuropsychology and Neuroscience Research, and Traumatic Brain Injury Research at Kessler Foundation discussed the use of strategy training in the cognitive rehabilitation of patients with MS and TBI.
The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine spoke about the challenge of OSA being underdiagnosed, and what her institution is doing to combat it.
Treatment with the Catabasis Pharmaceuticals small molecule oral NF-kB inhibitor resulted in improvements in the 10-meter walk/run scores, time-to-stand scores, and 4-stair climb scores in 31 steroid-naïve boys with DMD aged 4 to 7 years.
A newborn presents with new onset episodes of lateral gaze deviation with extremity stiffening.
Neurology News Network for the week ending October 5, 2019.
New 9-month data suggest that Sarepta Therapeutics’ investigational limb-girdle muscular dystrophy type 2E treatment, SRP-9003, is linked to improved functional measures and reduction in creatine kinase.
As vestibular migraine is a common cause of vertigo, the results, which need to be confirmed with larger studies, suggest some potential for an effective and easy to use treatment for patients.
Bernard Baumel, MD, and colleagues at the University of Miami have recently launched a clinical trial to examine the safety and efficacy of multiple doses of human mesenchymal stem cells in patients with Alzheimer disease.
Unsustainable costs pose challenges for patients and providers alike as the price of living with MS continues to rise.
The neurologist at the National MS Center and University Hospital, in Brussels, discussed the clinician mindset when treating women with MS who plan to get pregnant, and how patients using assistive reproductive treatments should be approached.
Mallinckrodt’s repository corticotropin injection (Acthar Gel) showed statistically significant results for every efficacy end point assessed, including the primary end point. Data will be shared at an upcoming medical meeting.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Fred Rincon, MD, MSc.
Originally approved by the FDA in January, sumatriptan nasal spray was acquired by Upsher-Smith in a territory rights agreement with Dr. Reddy’s Laboratories in June, as well as its 3-mg injection formulation (Zembrace SymTouch).
The chief medical officer at Harmony Biosciences discussed the takeaways from a number of data presentations of pitolisant’s efficacy and safety from World Sleep 2019.
Despite early reservations, available literature suggests that it may be time to invest in the utilization of wellness-based methods in the treatment of migraine.
Hauser, who is director of the UCSF Weill Institute for Neurosciences, spoke with NeurologyLive about the gravity of the phase 3 ASCLEPIOS I and II trial results in relapsing MS.
The senior research scientist in the Center for Mobility and Rehabilitation Engineering Research at Kessler Foundation spoke to the research being done into the functional implementation of exoskeletons in neurorehabilitation.
New classes of acute migraine therapies on the cusp of FDA approval look to fill in long-standing gaps in care.
The professor of chemistry and chemical biology at Harvard University and Blavatnik National Laureate discussed the work she and colleagues have done on microbiome metabolism and what upcoming plans to pursue this further could achieve.
The drug, the only approved botulinum toxin type B on the market, was recently approved for the treatment of chronic sialorrhea in adults.
The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the use of stem cell transplantation as a potential method of treating multiple sclerosis.
Year-long data presented at World Sleep 2019 suggest that Eisai’s lemborexant is safe and effective in treating adults with insomnia, supporting its recently submitted NDA. It is set to be reviewed by the FDA by late December.
